

March 14, 2008

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of International Corporate Finance  
100 F Street N.E., Mail Stop 3628  
Washington, DC 20549  
Phone: 202 551 3450

Re: Diamyd Medical AB  
File No. 82-34956  
Documents Furnished Pursuant to Rule 12g3-2(b)

**SUPPL**

Ladies and Gentlemen:

We hereby submit, pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934, as Amended, the enclosed press release of Diamyd Medical AB:

Press Release dated as of March 14, 2008: **"DIAMYD GETS AUTHORIZATION TO BEGIN PHASE III STUDY IN THE US"**

Kindly acknowledge receipt of the enclosed material by stamping the copy of this letter and returning it in the self-addressed stamped envelope provided.

Very truly yours,



Michael A. Christini

Enclosure  
cc: Cecilia Driving




**PROCESSED**

**MAR 25 2008**

**THOMSON  
FINANCIAL**

*llw 3/24*



RECEIVED  
MAR 21 A 9 22

## **DIAMYD GETS AUTHORIZATION TO BEGIN PHASE III STUDY IN THE US**

**Press Release, Stockholm, Sweden, March 14, 2008 – Diamyd Medical AB  
(www.omxgroup.com, ticker: DIAM B; www.otcqx.com, ticker DMYDY)**

Diamyd Medical announced today that the FDA has given the Company permission to start a Phase III clinical study in type 1 diabetes patients in the US.

“We are eager to start this study and to be able to offer this promising drug to our newly diagnosed type 1 diabetes patients”, says Professor Jerry Palmer, University of Washington in Seattle, USA, who will be the Lead Investigator for the US study.

“We are extremely pleased with the regulatory process, that has now enabled us to go ahead with the Phase III trial in the US,” says Elisabeth Lindner, president and CEO of Diamyd Medical. “Over the past months we have received dozens of patient inquiries with requests to participate in our Phase III type 1 diabetes studies in the US and in Europe. It is very satisfying to be able to start the studies now.”

The US Phase III study will enroll 306 new-onset type 1 diabetes patients, who are within 3 months of diagnosis. In one arm of the study, 102 patients will receive a 20 µg injection of Diamyd® on study days 1 and 30 to confirm earlier Phase II results. In a second arm, 102 patients will receive a 20 µg injection of Diamyd® on days 1 and 30, and then additional doses on days 90 and 270 to investigate the potential long-term beneficial effect of extra doses. In the third arm of the study, 102 patients will receive placebo. Results of the study will be analyzed 15 months after all patients have received their 1<sup>st</sup> injection. A parallel similar Phase III study is planned to be conducted in Europe and together, pending a positive outcome of the trials, the studies can be used for market registration of the drug.

In a previous Phase II study in young type 1 diabetes patients, the Diamyd® diabetes vaccine showed efficacy in preserving the patients’ own insulin producing capacity for at least 30 months. No safety concerns have to date been reported in any clinical study with Diamyd®.

“The Phase II study results are amazingly good, and they shall now be confirmed in the Phase III program”, says Professor Ludvigsson, Principal Investigator for the previous Phase II study in Sweden and the Principal Investigator for the upcoming European Phase III study. “It is the first time that we have been able to show a real effect on the progress of type 1 diabetes, without causing any side effects, and it gives true hope for patients. Saving insulin producing cells from being destroyed by the autoimmune process in type 1 diabetes is of great clinical value as it makes it easier for the patient to handle the disease with reduced acute and late complications.”

**About Diamyd Medical**

Diamyd Medical is a biopharmaceutical company developing treatments for diabetes and its complications. The company's furthest developed project is the GAD-based drug Diamyd<sup>®</sup> for autoimmune diabetes for which Phase III studies are planned. Diamyd<sup>®</sup> has demonstrated significant and positive results in Phase II clinical trials in Sweden.

GAD65, a major auto antigen in autoimmune diabetes, is the active substance in Diamyd. GAD65 is also an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory transmitter GABA. In this context, GAD may have an important role not only in diabetes but also in several central nervous system-related diseases. Diamyd Medical has an exclusive worldwide license from the University of California at Los Angeles regarding the therapeutic use of the GAD65 gene.

Diamyd Medical has sublicensed its UCLA GAD Composition of Matter license to Neurologix, Inc. in Fort Lee, New Jersey for treatment of Parkinson's disease.

Other projects comprise drug development within therapeutic gene transfer using the exclusively licensed and patent protected Nerve Targeting Drug Delivery System (NTDDS). The company's lead NTDDS projects include enkephalin and GAD for chronic pain, e.g., diabetes pain or cancer pain.

Diamyd Medical has offices in Stockholm, Sweden and Pittsburgh, PA. The Diamyd Medical share is quoted on the Stockholm Nordic Exchange in Sweden (NOMX ticker: DIAM B) and on the OTCQX-list in the United States (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available at [www.diamyd.com](http://www.diamyd.com).

For further information, please contact:

**Stockholm office**

Elisabeth Lindner

CEO and President

+46 8 661 0026

[elisabeth.lindner@diamyd.com](mailto:elisabeth.lindner@diamyd.com)

**Stockholm office**

Anders Essen-Möller

Chairman

+46 8 661 0026

[anders.essen-moller@diamyd.com](mailto:anders.essen-moller@diamyd.com)

**Pittsburgh office**

Michael Christini

President

+1 412 770 1310

[michael.christini@diamyd.com](mailto:michael.christini@diamyd.com)

**Diamyd Medical AB (publ), Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 8 661 00 26, fax: +46 8 661 63 68 or E-mail: [info@diamyd.com](mailto:info@diamyd.com). VATno: SE556530-142001.**

*This document contains certain "statements" which constitute forward-looking information. These statements, including statements relating to the company's future, and its plans, are based on current expectations and assumptions. These statements are subject to change and are not intended to constitute a contract. These statements can be affected by inaccurate assumptions or by other unforeseen events and circumstances. Diamyd Medical undertakes no obligation to publicly update or revise these statements at any time for any reason. These statements are the property of Diamyd Medical and are not to be distributed outside the company. This document is a translation from the Swedish original. No guarantee is made that the translation is free from errors.*

**END**